Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
about
Convergence of nanotechnology and cancer prevention: are we there yet?Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticlesAssembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids.Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen.Oral bioavailability enhancement through supersaturation: an update and meta-analysis.
P2860
Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Silica-lipid hybrid (SLH) vers ...... oral absorption of celecoxib.
@en
type
label
Silica-lipid hybrid (SLH) vers ...... oral absorption of celecoxib.
@en
prefLabel
Silica-lipid hybrid (SLH) vers ...... oral absorption of celecoxib.
@en
P2860
P1476
Silica-lipid hybrid (SLH) vers ...... t oral absorption of celecoxib
@en
P2093
Andrew K Davey
P2860
P304
P356
10.1007/S11095-011-0458-X
P577
2011-05-11T00:00:00Z